3Q EARNINGS: Biogen's MS pill Tecfidera blows away estimates, fuels overall sales growth
This article was originally published in Scrip
Executive Summary
Biogen Idec said surging sales of its new multiple sclerosis drug Tecfidera fueled better than expected revenue and profit in the third quarter.